Health Canada’s recent reminder to licensed producers about the rules governing facility visits hasn’t introduced new regulations, but it has shown that possibilities for meaningful compliant tours may be far narrower than previously assumed.
For years, tours have served as a tool for producers to build brand equity, attract investors, and demonstrate quality in a highly regulated market. But the latest guidance appears to shift how the regulator interprets who should be allowed inside a cannabis facility and why.
“Changes to internal policies and SOPs are mostly reactive,” said Sherry Boodram, CEO of CannDelta. She added that producers are already navigating “sustained price compression, regulatory burden, and margin pressure that has pushed many operators to the edge of viability.”
In that environment, tours have served a practical purpose beyond marketing.
“Tour programming, whether for consumers, investors, or B2B partners, has been one of the few tangible ways producers can build brand equity, attract capital, and communicate quality directly,” added Boodram.
Health Canada’s guidance doesn’t explicitly ban tours. Instead, it emphasizes that access to cannabis facilities must be limited to individuals whose presence is required for operational or regulatory purposes. That distinction, long understood to apply primarily to employees, is now being interpreted more broadly. Boodram said this reinterpretation is at the heart of the current uncertainty.
“What Health Canada’s guidance has done is apply the access restriction language… more broadly to anyone stepping through the door,” she explained, adding that whether this reflects original legislative intent or an evolved interpretation is still up for debate.
Read the full story at StratCann
